An update on topical therapies for psoriasis.

Emily K Pender, Brian Kirby

Journal: Current opinion in rheumatology 2024;36(4):289-294

PMID: 38651512

Abstract

PURPOSE OF REVIEW

Topical therapies are a mainstay of treatment for mild psoriasis and may be a useful adjunct in treatment of moderate-to-severe psoriasis. This review summarizes recent advances in topical therapies for psoriasis and currently available treatments.

RECENT FINDINGS

Topical aryl hydrocarbon receptor modulators (tapinarof) and topical phosphodiesterase-4 inhibitors (roflumilast) have been proven effective in randomized controlled trials for psoriasis. Although topical JAK inhibitors have also been studied, none are currently licensed for treatment of psoriasis. Topical corticosteroids and vitamin D analogues remain the most commonly used and widely available topical treatments for psoriasis. Cost may limit use of novel topical agents.

SUMMARY

Although the novel topical agents tapinarof and roflumilast are licensed for treatment of psoriasis by the FDA in the United States, they have not yet been licensed in Europe, and it remains to be seen whether they will be limited by cost.

Address: St Vincent's University Hospital, Elm Park.; St Vincent's University Hospital, Elm Park.; Charles Institute of Dermatology, University College Dublin, Belfield, Dublin 4, Ireland.

DOI: 10.1097/BOR.0000000000001018

Link outs

Free resources

Medical:

https://medlineplus.gov/psoriasis.html

Research Materials:

https://antibodies.cancer.gov/detail/CPTC-BRIP1-5

Subscription / membership required

Full Text Sources:

MeSH Terms: Humans, Psoriasis, Phosphodiesterase 4 Inhibitors, Cyclopropanes, Aminopyridines, Benzamides, Administration, Topical, Adrenal Cortex Hormones, Vitamin D, Dermatologic Agents, Niacinamide, Resorcinols, Stilbenes